Iodine-124

Phase 2Radiopharmaceutical

SStanford University

Iodine-124 is one of 76 small molecule programs targeting Thyroid Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thyroid CarcinomaActive, not recruiting

Breast CancerActive, not recruiting

Thyroid CancerActive, not recruiting

Thyroid CarcinomaPhase 1

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Thyroid CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

Avastin

BBio-Thera Solutions

Preclinical

153 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

DATROWAY

Daiichi Sankyo

Preclinical

4 5

Voltaren

Novartis

Preclinical

1 6

Blenoxane

Bristol-Myers Squibb

Preclinical

1 7

Iodine-124

SStanford University

Phase 2

1 8

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 9

Tricor

JJagotec

Preclinical

1 10

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Thyroid Carcinoma

NCT03647358

Clinical

Trials by Indication[1]

Recurrent1 trial

Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA

Withdrawn·SStanford University··NCT00373711

Thyroid Cancer1 trial

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

Recruiting·TThomas Hope·Phase 2·NCT06961084·62 enrolled

Thyroid Carcinoma1 trial

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03647358·60 enrolled

Breast Cancer1 trial

Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT

Terminated·SStanford University·Phase 1·NCT00725946·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Iodine-124. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iodine-124 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iodine-124. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 2[1]
Company: SStanford University

Iodine-124

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Recurrent1 trial

Thyroid Cancer1 trial

Thyroid Carcinoma1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News